NSD2 and AL amyloidosis: Indeed cell lines expressing this fusion protein display significantly elevated levels of global H3K36me2, as expected for elevated expression of a catalytically active NSD2 fusion protein, and shRNA knockdown of NSD2 in t(4;14) multiple myeloma cell lines results in an antiproliferative phenotype, strongly suggesting that therapeutic targeting of NSD2 in the context of the t(4;14) fusion protein may be an effective means of treating this subset of multiple myeloma.